Clinical Trial Detail

NCT ID NCT03220009
Title Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

mucosal melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.